Immunoglobulin G4-related Autoimmune Pancreatitis and Hypopituitarism Following Immune Checkpoint Inhibitor Therapy.
A 70-year-old man underwent nephrectomy for renal cell carcinoma followed by 3 cycles of pembrolizumab as adjuvant chemotherapy.
APA
Inoue S, Tsunoda Y, et al. (2025). Immunoglobulin G4-related Autoimmune Pancreatitis and Hypopituitarism Following Immune Checkpoint Inhibitor Therapy.. Internal medicine (Tokyo, Japan), 64(2), 209-215. https://doi.org/10.2169/internalmedicine.3591-24
MLA
Inoue S, et al.. "Immunoglobulin G4-related Autoimmune Pancreatitis and Hypopituitarism Following Immune Checkpoint Inhibitor Therapy.." Internal medicine (Tokyo, Japan), vol. 64, no. 2, 2025, pp. 209-215.
PMID
38811225
Abstract
A 70-year-old man underwent nephrectomy for renal cell carcinoma followed by 3 cycles of pembrolizumab as adjuvant chemotherapy. Three months later, he complained of appetite loss. He was diagnosed with secondary adrenal insufficiency and pancreatic tumor. Amylase and immunoglobulin G (IgG) 4 levels were normal. The differential diagnosis poses challenges in distinguishing pancreatic cancer, renal cell carcinoma metastasis, and autoimmune pancreatitis, necessitating tumor resection surgery. A histological examination revealed IgG4-related sclerosing pancreatitis. Postoperatively, there was no recurrence of pancreatitis. It is essential to consider the potential development of IgG4-related diseases after the administration of immune checkpoint inhibitors.
MeSH Terms
Humans; Male; Aged; Immune Checkpoint Inhibitors; Autoimmune Pancreatitis; Carcinoma, Renal Cell; Hypopituitarism; Kidney Neoplasms; Immunoglobulin G4-Related Disease; Antibodies, Monoclonal, Humanized; Immunoglobulin G
같은 제1저자의 인용 많은 논문 (4)
- Safe and Effective Use of Nivolumab Monotherapy for Locally Advanced Cutaneous Squamous Cell Carcinoma in a 100-Year-Old Patient.
- Predictive model for pancreatic fistula in minimally invasive surgery for gastric cancer.
- Urinary biomarkers for immunotherapy response in urothelial carcinoma: current status and future outlook.
- Response to Letter to the Editor: "In Patients Receiving Pembrolizumab, Adverse Effects on the Pituitary Gland, Heart and Kidneys Must Be Excluded".